A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of VGT-309
Latest Information Update: 29 Oct 2021
At a glance
- Drugs VGT 309 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Vergent Bioscience
- 28 Oct 2021 Status changed from not yet recruiting to completed.
- 20 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 24 Sep 2020 New trial record